Designing Treatment Plans Research Articles

Abstract 6018: The perfused 3DKUBE™ rare tumor assay models in vivo drug response

Abstract Models that accurately reflect patient drug response are essential for the clinical design of personalized treatment plans and necessary for preclinical drug development. The advancement of predictive models for rare tumor types is impeded in part, by the relative scarcity of fresh tumor tissue available for study. To address the problem of tissue availability we have developed a label-free, combined functional and chemical selection method for the isolation of rare tumor cancer stem cells (CSC) and circulating tumor cells (CTC) from primary patient tissue and blood. Enriched cells were expanded as 3D microtumors under optimized conditions, validated as CSC through in vivo tumorigenesis studies, and characterized by correlative genomic, proteomic/phosphoproteomic, and phenomic analysis. We found isolation and expansion by this method yielded a source of primary cells suitable for live, cell-based predictive drug screening in multiple rare tumor derived models of neuroendocrine and mesenchymal origin, including locally or regionally advanced and metastatic SCLC, recurrent Merkel Cell Carcinoma, recurrent osteosarcoma and dermatofibrosarcoma protuberans. The 3DKUBE™ rare tumor assay was performed using validated CSCs cultured as perfused 3D microtumors (pMTs). Drug studies using the perfused, 3DKUBE™ rare tumor assay modeled individual patient response better than CSC-based or 3D static microtumor-based drug screens and thus demonstrate the effectiveness of this platform for predictive modeling of individual patient drug response. Taken together, this system provides a means of performing ex vivo drug response experiments on very small tissue samples, including core biopsies, with relevant results for patients. Citation Format: Melissa Millard, Kathryn M. Appleton, Ashley Elrod, Nicholas W. Bateman, Tamara Abulez, Kelly Conrads, Brian Hood, Thomas P. Conrads, Lillia M. Holmes, Teresa M. DesRochers. The perfused 3DKUBE™ rare tumor assay models in vivo drug response [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6018.

Serum zinc and copper levels in a sample of Egyptian epileptic children

BackgroundEpilepsy is among the most common disabling neurological disorders among children. Altered serum levels of zinc and copper may facilitate seizure occurrence and repetition, and antiepileptic drugs may disturb their serum levels affecting disease control and outcome.ObjectiveTo investigate the association between serum levels of zinc and copper and epilepsy and antiepileptic treatment in a group of Egyptian epileptic children.MethodsCase-control study on 100 epileptic patients, aged from 2 to 16 years, from neurology outpatient clinic and 50 apparently healthy children with matched age and sex. Venous samples were withdrawn from patients and controls then serum levels of zinc and copper were measured with graphite furnace atomic absorption spectrometer-A Analyst 800.ResultsSerum zinc level of patients’ group was significantly lower than that of controls with a mean of 59.1 μ/dL ± 22.7 and 85 μ/dL ± 22.2, respectively (P < 0.01). Serum zinc level of patients with history of febrile seizures was significantly decreased compared to patients without history of febrile seizures with a mean of 41.5 μ/dL ± 20.1 and 67.9 μ/dL ± 19.3, respectively (P < 0.01). Patient on carbamazepine intake showed significantly lower zinc serum level than patients without carbamazepine intake, with a mean of 49.0 μ/dL ± 17 and 61.8 μ/dL ± 23.4, respectively (P < 0.01). A significant negative correlation was noted between the duration of illness of epilepsy and the mean copper serum level (P < 0.05).ConclusionZinc and copper altered homeostasis have mounting evidence about their role in the pathogenesis of epilepsy. Designing treatment plans that selectively restore zinc and copper normal levels may be a beneficial strategy in the future.

Physicians' and pharmacists' perception and practice of hospital pharmacist professional role in Egypt.

This study aimed to investigate physicians' and pharmacists' perceptions of the importance of pharmacists' role in healthcare in Egypt, and actual delivery of these roles in practice. Identifying any differences and inconsistencies between these will inform future strategies that maximize pharmacists' professional contribution to hospital practice. A self-administered questionnaire using a 5-point Likert scale was distributed to a convenience sample of physicians (500) and pharmacists (500) practicing in selected private or public hospitals in Egypt. The main sections of the questionnaire comprised statements that pertained to physicians'/pharmacists' views on the importance of pharmacists' roles and their actual delivery in practice. In this study, physicians showed low scores for both the importance of and the delivery of advanced patient-facing clinical pharmacy roles such as suggesting prescription medications, and designing treatment plans. In comparison, pharmacists were more positive on both of these aspects of their roles. High mean scores were reported by the physicians for pharmacist's traditional roles such as patient counselling, assessing compliance, preventing medication errors and treating minor illnesses. Both physicians and pharmacists reported poor pharmacists practice as drug information resources despite their high perception of the importance of that role. This study suggested that in hospitals in Egypt, there are significant differences between physicians' and pharmacists' perception and practice, and pharmacists' clinical skills are underutilized in health care.

Building Clinical Nutrition Capacity in Lao PDR: A Novel Clinical Nutrition Educational Model to Provide Interventions to Treat Malnutrition and Non-Communicable Diseases

Abstract Objectives Malnutrition is the number one health priority in Lao PDR where 36% of children under the age of five are stunted and 27% are underweight. Compounded by escalating rates of diabetes and non-communicable diseases, hospital-based nutrition interventions are needed. A partnership between OHSU and the Lao Ministry of Health is working to fill the gap in knowledge and application by providing clinical nutrition education to health care providers. Methods A clinical nutrition needs assessment was conducted in early 2016 and informed the design of a 1000-hour, evidenced-based applied clinical dietetics certificate program for health professionals. Aligning with the 2015 International Dietitian Education Program (IDE) standards, the curriculum was adapted to be culturally relevant and appropriate. Semi-structured interviews, open-ended questions, and pre-and post-tests were used to evaluate the program. Results As of January 2020, 32 clinicians have successfully completed the program. At matriculation, the mean pre-test score was 43% and 50% of students could not calculate BMI or waist-to-hip ratio, determine individual energy, nutrient and fluid requirements, provide individualized medical nutrition therapy, or manage severe acute malnutrition. The mean final exam score was 84% with greatest improvements in malnutrition (+94%) and chronic disease (+62%) knowledge and application. Upon completion, 98% of students successfully met IDE competency standards, conducted nutrition-focused physical exams, administered culturally appropriate nutrition interventions, and provided nutrition education to medical teams at provincial hospitals. Conclusions Providing hands-on training on nutrition assessment, differential diagnosis, and treatment plan design and implementation enables health care providers in Lao PDR to better treat patients with malnutrition and non-communicable diseases that are prevalent within this developing country. This educational curriculum may serve as a model for other developing countries. Funding Sources OHSU Global-SE Asia, OHSU Graduate Programs of Human Nutrition and the Vejdusit Foundation

Acute toxicity outcomes and dosimetric implications from incidental irradiation of adjacent tissues in tangent field hypofractionated breast radiotherapy.

Adjacent tissues-in-beam (TIB) may receive substantial incidental doses within standard tangent fields during hypofractioned whole breast irradiation (HF-WBI). To characterize the impact of dose to TIB, we analyzed dosimetric parameters of TIB and associated acute toxicity. Plans prescribed to 40.5 Gy/15 fractions from 4/2016-1/2018 were evaluated. Structures of interest were contoured: (1) TIB: all tissues encompassed by plan 30% isodose lines, (2) breast, (3) non-breast TIB (nTIB): TIB minus contoured breast. Volumes of TIB, breast, and nTIB receiving 100%-107% of prescription dose (V100-V107) were calculated. Twelve patient- and physician-reported acute toxicities were prospectively collected weekly. Correlations between volumetric and dosimetric parameters were assessed. Uni- and multivariable logistic regressions evaluated toxicity grade changes as a function of TIB, breast, and nTIB V100-V107 (in cm3). We evaluated 137 plans. Breast volume was positively correlated with nTIB and nTIB V100 (rho = 0.52, rho = 0.30, respectively, both p < 0.001). V107 > 2 cm3 were noted in 14% of breast and 21% of nTIB volumes. On multivariable analyses, increasing breast and nTIB V100 significantly raised odds of grade 2+ dermatitis and burning/twinging pain, respectively; increasing nTIB V105 elevated odds of hyperpigmentation and burning pain; and increasing nTIB V107 raised odds of burning pain. Threshold volumes for >6-fold odds of developing burning pain were TIB V105 > 100 cm3 and V107 > 5 cm3. For HF-WBI, doses to nTIB over the prescription predicted acute toxicities independent of breast doses. These data support inclusion of TIB as a region of interest in treatment planning and protocol design.

Redressing responses to the treatment gap for people with alcohol problems: The overlooked role of untreated remission from alcohol problems

Abstract. Aims: The “treatment gap” for people with alcohol problems has been identified as very large in the literature. An array of responses to the treatment gap have been focussed upon, including changing the perceptions of untreated people in order to make them want treatment more. A separate approach identifies the treatment system itself as the cause of the treatment gap. The aim of this paper was to consider research on untreated remission from alcohol problems to better understand responses to the treatment gap. Methodology: Three areas of existing published literature were thematically reviewed and synthesised: treatment gap research, untreated remission from alcohol problems research, and treatment planning and system design research. Results: Including rates of untreated remission from alcohol problems reduces the size of the treatment gap considerably. Treatment planning models which estimate unmet demand are better suited than unmet need when identifying gaps in service provision. Responding to the treatment gap requires broadening the treatment system beyond the specialised setting, and the assumptions associated with the process and expected outcomes of remission may need revisiting. Conclusions: Treatment planning models are useful when identifying gaps in service provision, but more sophisticated inclusion of untreated remission data is required. The treatment response may need to be diversified to support the life circumstances and perspectives of people with alcohol problems, with one example (outlined in this paper) being the provision of digital support services.

The Promising Connection Between Data Science and Evolutionary Theory in Oncology.

Theoretical and empirical work over the past several decades suggests that oncogenesis and disease progression represents an evolutionary story. Despite this knowledge, current anti-resistance strategies to drugs are often managed through treating cancers as independent biological agents divorced from human activity. Yet once drug resistance to cancer treatment is understood as a product of artificial or anthropogenic rather than unconscious selection, oncologists could improve outcomes for their patients by consulting evolutionary studies of oncology prior to clinical trial and treatment plan design. In the setting of multiple cancer types, for example, a machine learning algorithm can predict the genetic changes known to be related to drug resistance. In this way, a unity between technology and theory might have practical clinical implications—and may pave the way for a new paradigm shift in medicine.

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network

BackgroundThe European Medicine Agency granted marketing approval to 164 orphan medicinal products for rare diseases, among which 28 products intended for the treatment of hereditary metabolic diseases. Taking advantage of its privileged connection with 69 healthcare centres of excellence in this field, MetabERN, the European Reference Network for hereditary metabolic diseases, performed a survey asking health care providers from 18 European countries whether these products are available on the market, reimbursed and therefore accessible for prescription, and actually delivered in their centre.ResultsResponses received from 52 centres (75%) concerned the design of treatment plans, the access to marketed products, and the barriers to delivery. Treatment options are always discussed with patients, who are often involved in their treatment plan. Most products (26/28) are available in most countries (15/18). Among the 15 broadly accessible products (88.5% of the centres), 9 are delivered to most patients (mean 70.1%), and the others to only few (16.5%). Among the 10 less accessible products (40.2% of the centres), 6 are delivered to many patients (66.7%), and 4 are rarely used (6.3%). Information was missing for 3 products. Delay between prescription and delivery is on average one month. Beside the lack of availability or accessibility, the most frequent reasons for not prescribing a treatment are patients’ clinical status, characteristic, and personal choice.ConclusionsData collected from health care providers in the MetabERN network indicate that two-third of the orphan medicines approved by EMA for the treatment of hereditary metabolic diseases are accessible to treating patients, although often less than one-half of the patients with the relevant conditions actually received the approved product to treat their disease. Thus, in spite of the remarkable achievement of many products, patients concerned by EMA-approved orphan medicinal products have persistent unmet needs, which deserve consideration. The enormous investments made by the companies to develop products, and the high financial burden for the Member States to purchase these products emphasize the importance of a scrupulous appreciation of treatment value involving all stakeholders at early stage of development, before marketing authorization, and during follow up.

Prediction Model for Audiological Outcomes in Patients With GJB2 Mutations.

Recessive mutations in GJB2 are the most common genetic cause of sensorineural hearing impairment (SNHI) in humans. SNHI related to GJB2 mutations demonstrates a wide variation in audiological features, and there has been no reliable prediction model for hearing outcomes until now. The objectives of this study were to clarify the predominant factors determining hearing outcome and to establish a predictive model for SNHI in patients with GJB2 mutations. A total of 434 patients confirmed to have biallelic GJB2 mutations were enrolled and divided into three groups according to their GJB2 genotypes. Audiological data, including hearing levels and audiogram configurations, were compared between patients with different genotypes. Univariate and multivariate generalized estimating equation (GEE) analyses were performed to analyze longitudinal data of patients with multiple audiological records. Of the 434 patients, 346 (79.7%) were homozygous for the GJB2 p.V37I mutation, 55 (12.7%) were compound heterozygous for p.V37I and another GJB2 mutation, and 33 (7.6%) had biallelic GJB2 mutations other than p.V37I. There was a significant difference in hearing level and the distribution of audiogram configurations between the three groups. Multivariate GEE analyses on 707 audiological records of 227 patients revealed that the baseline hearing level and the duration of follow-up were the predominant predictors of hearing outcome, and that hearing levels in patients with GJB2 mutations could be estimated based on these two parameters: (Predicted Hearing Level [dBHL]) = 3.78 + 0.96 × (Baseline Hearing Level [dBHL]) + 0.55 × (Duration of Follow-Up [y]). The baseline hearing level and the duration of follow-up are the main prognostic factors for outcome of GJB2-related SNHI. These findings may have important clinical implications in guiding follow-up protocols and designing treatment plans in patients with GJB2 mutations.

Automatic Localization of Landmarks in Craniomaxillofacial CBCT Images Using a Local Attention-Based Graph Convolution Network.

Landmark localization is an important step in quantifying craniomaxillofacial (CMF) deformities and designing treatment plans of reconstructive surgery. However, due to the severity of deformities and defects (partially missing anatomy), it is difficult to automatically and accurately localize a large set of landmarks simultaneously. In this work, we propose two cascaded networks for digitizing 60 anatomical CMF landmarks in cone-beam computed tomography (CBCT) images. The first network is a U-Net that outputs heatmaps for landmark locations and landmark features extracted with a local attention mechanism. The second network is a graph convolution network that takes the features extracted by the first network as input and determines whether each landmark exists via binary classification. We evaluated our approach on 50 sets of CBCT scans of patients with CMF deformities and compared them with state-of-the-art methods. The results indicate that our approach can achieve an average detection error of 1.47mm with a false positive rate of 19%, outperforming related methods.

Risk Factors for Incidence and Prognosis in Chondrosarcoma Patients with Pulmonary Metastasis at Initial Diagnosis.

BackgroundThe incidence and prognostic factors of chondrosarcoma patients have been reported in early studies. However, the association between risk factors and the incidence or prognosis of chondrosarcoma patients with pulmonary metastasis remains unclear. Therefore, we assessed these risk factors among chondrosarcoma patients with pulmonary metastasis.Material/MethodsFrom 1365 chondrosarcoma patients in the Surveillance, Epidemiology, and End Results (SEER) database, we collected the information of 69 patients with pulmonary metastasis at the initial diagnosis of chondrosarcoma from 2010 to 2016. We investigated the incidence, risk factors, and prognostic factors for pulmonary metastasis patients by using multivariate logistic regression and multivariate Cox regression analyses.ResultsData from a total of 69 (6.8%) chondrosarcoma patients with pulmonary metastasis at initial diagnosis were extracted. Patients with the following characteristics were positively associated with higher risk of pulmonary metastasis: dedifferentiated subtype, high grade of malignancy, extracompartmental tumor (Enneking B), presence of regional lymph nodes, local recurrence, large tumor size (larger than 15 cm), and being married. Older patients (older than 67 years), and patients with clear cell chondrosarcoma or large tumor size (larger than 15 cm) exhibited the worse prognosis and survival (overall and cancer-specific). Resection of the primary tumor tended to be correlated with a better prognosis.ConclusionsThe incidence of pulmonary metastasis in chondrosarcoma was approximately 6.8%, with poor prognosis. Identifying risk factors and their associations with the incidence and prognosis in chondrosarcoma patients with pulmonary metastasis could provide a reference for clinical surveillance and guide the design of personalized treatment plans.

Thyroid dose‐volume thresholds for the risk of radiation‐related hypothyroidism in nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy—A single‐institution study

BackgroundTo identify thyroid dose‐volume thresholds for radiotherapy (RT)‐related hypothyroidism (HT) in patients with nasopharyngeal carcinoma (NPC) treated with intensity‐modulated RT (IMRT). In this way, we desired to guide the design of treatment plans and, finally, lower HT prevalence.MethodsIn total, 345 NPC patients treated with IMRT were evaluated retrospectively during a median follow‐up of 45.2 (range, 11.3‐64.9) months. Serum‐based assessments of thyroid function before and after IMRT were monitored periodically. Thyroid dose‐volume parameters were analyzed for their association with HT risk.ResultsIn total, 44.1% of patients (152/345) developed primary HT. Analyses of thyroid dose‐volume parameters identified a stringent dose‐volume histogram (DVH) threshold defined by V 25Gy (the percentage thyroid volume that receives >25 Gy, not the absolute volume) ≤60%, V 35Gy ≤ 55%, and V 45Gy ≤ 45%. Patients whose thyroid DVHs satisfied these constraints had a lower prevalence of 2‐year HT compared with the overall prevalence (13.2% vs 25.8%, P < .001). Another DVH was defined by V 25Gy > 95%, V 35Gy > 90%, and V 45Gy > 75%, and patients whose thyroid DVHs satisfied with these constraints had a higher prevalence of 2‐year HT than the overall incidence (36.0% vs 25.8%, P < .001).ConclusionWe recommend V 25Gy ≤ 60%, V 35Gy ≤ 55%, and V 45Gy ≤ 45% as the “stringent” DVH line, and V 25Gy > 95%, V 35Gy > 90%, and V 45Gy > 75% as the “inhibition” DVH line, under the precondition of not compromising the target coverage. These findings could help in the design of individual treatment plans and, eventually, to lowering of HT prevalence.

Irradiation of regional lymph node areas in breast cancer – Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design

ObjectiveThe purpose of this study was to estimate the dose distribution from randomized trials (MA.20, EORTC 22922-10925 (EORTC), AMAROS and the Z0011 trial) on lymph node (LN) irradiation on a large LN atlas. Methods580 F18-FDG-PET/CT positive LN metastases of 235 patients were transferred rigidly and non-rigidly to three “template CTs” (standard, obese and slender patient). Further, the LN clinical target volumes (CTVs) were contoured according to the ESTRO-guidelines. Treatment plans were designed (each for the left and right side) for all patients based on the study protocols of the MA.20, EORTC, AMAROS and Z0011 trial. Subsequently, the dose distribution in the ESTRO-CTVs and in the 580 LNs were assessed. ResultsOur results reveal variable dose coverage (26.8 ± 17.3 Gy–53.0 ± 1.8 Gy) in the targeted LN areas (ESTRO-CTV and LN) in dependence of the treatment planning design and the patients’ body shape. None of the treatment plan designs provided full dose coverage to the lymphatic drainage system. High tangent irradiation resulted in a similar dose distribution in L I and II compared to the AMAROS field design. ConclusionInclusion of the entire lymphatic system may not be necessary for all patients to reproduce the oncologic benefit shown in the randomized LN-irradiation trials. Inclusion of axillary level II and extension of the supraclavicular CTV can be considered in selected high-risk patients, based on dose recalculation of the MA.20 trial. Further, our results amplify earlier assumptions that irradiation may have accounted for the good results after SLND alone in the Z0011 trial.

Nomogram predicting long-term overall survival and cancer-specific survival of lip carcinoma patients based on the SEER database

Our study was designed to construct nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of lip carcinoma patients.A search of the Surveillance, Epidemiology, and End Results (SEER) database provided us with detailed clinical data of the 1780 lip carcinoma patients. On the basis of the credible random split-sample method, the 1780 patients were placed into 2 groups, with 890 patients in the modeling group and 890 patients in the counterpart's group (proportion = 1:1). By employing Kaplan–Meier univariate and Cox multivariate survival analyses based on the modeling cohort, the nomograms were developed and then used to divide the modeling cohort into low-risk cohort and high-risk cohort. The survival rates of the 2 groups were calculated. Internal and external evaluation of nomogram accuracy was performed by the concordance index (C-index) and calibration curves.With regard to 5- and 8-year OS and CSS, the C-indexes of internal validation were 0.762 and 0.787, whereas those of external validation reached 0.772 and 0.818, respectively. All the C-indexes were higher than 0.7. The survival curves of the low-risk cohort were obviously better than those of the high-risk cohort.Credible nomograms have been established based on the SEER large-sample population research. We believe these nomograms can contribute to the design of treatment plans and evaluations of individual prognosis.

Effective Cancer Genotyping-Many Means to One End.

Precision cancer medicine requires effective genotyping of every patient's tumor to optimally design treatment plans. Despite its imperfect sensitivity, the rapidity and convenience of cell-free DNA sequencing makes it an essential complement to tumor genotyping, which, when used appropriately, can aid the pursuit of effective genotyping for all patients.See related article by Leighl et al., p. 4691.

Criteria for immediate placement of oral implants – a mini review

The introduction of osseointegrated implants in dentistry represents a turning point in dental clinical practice. Thanks to their multiple therapeutic possibilities and the high predictability of success, implant therapy is now regarded as an extremely reliable approach to replace missing teeth. The concept of immediate implant loading has become popular due to less trauma, reduced overall treatment time, decreased patient’s anxiety and discomfort, high patient acceptance and better function, and esthetics. Nonetheless, research and understanding in this area are confusing and sometimes contradictory. Hence, the purpose of this review to provide clinical benefits of immediate implants, and analyze criteria for immediate placement. Results from this review indicated that dental implants that are immediately placed into carefully selected extraction sockets have high survival rates comparable to implants placed in healed sites. However, a careful case selection, proper treatment plan, meticulous surgery, and proper design of prosthesis are essential for optimal outcomes when this approach is adopted.

Quantitative analysis of calcium oxalate hydrate urinary stones using FTIR and 950/912 cm−1 peak ratio

The ability to determine urinary-stone composition is valuable for urologists, allowing them to identify the possible causes of stone formation and to provide appropriate drug treatment and diet-control advice to patients, which can lower recurrence rates. Calcium-based stones account for the majority of urinary stones seen in patients, and calcium oxalate comprises most of these calcium-based stones. This study accomplishes a quantitative analysis of two forms of calcium oxalate stone, those comprised of calcium oxalate monohydrate (COM) or calcium oxalate dihydrate (COD), using Fourier transform infrared spectroscopy (FTIR). The use of a newly validated absorption peak ratio, 950/912 cm−1 (corresponding to COM and COD, respectively), is demonstrated to achieve quantitative estimation of the COM and COD composition. The correlation coefficient between the COM/(COM + COD) composition ratio and the selected peak ratio is 0.99 for standard compound mixtures. This peak-ratio analysis method could aid clinicians in quantitatively determining the COM and COD compositions of calcium oxalate stones, facilitating the design of appropriate treatment plans and preventive measures for calcium-oxalate-stone patients.

Exercise as a Treatment for Chronic Pain

Exercise as a Treatment for Chronic Pain

Factors affecting treatment motivation among Turkish patients receiving inpatient treatment due to alcohol/substance use disorder

Motivation is a significant factor in the treatment of addiction and has been proven to be a predictor of treatment outcomes. The present study investigated the effects of clinical variables, perceived social support, temperament, and personality traits on treatment motivation. This study included 100 patients whose detoxification treatment was completed following hospitalization in Alcohol and Drug Research, Treatment, and Training Center (AMATEM). Treatment motivations were assessed through Motivation for Treatment scale (MfT). Addiction Profile Index (API) was used to evaluate drug use characteristics, craving, and the effects of drug use on life. Temperament and character traits and perceived social support were evaluated by Temperament and Character Inventory (TCI) and Multidimensional Scale of Perceived Social Support (MSPSS), respectively. The number of treatment admissions, presence of a history of previous inpatient treatment, completed inpatient treatment, social support from the family, harm avoidance, substance use characteristics, craving, and the effect of substance on life showed differences while motivations of the patients were compared. Presence of a history of previously completed inpatient treatment, presence of high social support from the family, and significant recognition of the effects of substance on own life were evaluated as the factors predicting high motivation. The present study demonstrated that social support from family, previously completed inpatient treatment, and effect of substance in life had significant impact on motivation. Therefore, the assessment of these factors will aid in better understanding this population and in the design of long-term treatment plans.

Analysis of imaging features and treatment strategies of unilateral maxillary sinus and nasal diseases

Objective: To analyze the imaging features of unilateral maxillary sinus nasal lesions and the selection of treatment strategies based on imaging findings for these lesions. Method: The CT and enhanced MRI data of 64 cases of unilateral maxillary sinus and nasal lesions were selected. The imaging findings and surgery approach were observed and recorded. To summarize the imaging characteristics and analyze the choice of treatment strategy. Result: All 64 Unilateral maxillary sinus nasal lesions presented a roughly uniform soft tissue density shadow on CT. In all benign lesions, there were 9 cases manifested maxillary sinus wall bone destruction and bone discontinuity(18.4%,9/49); There were 17 cases of bone hyperplasia (34.7%,17/49).Bone destruction was observed in 14 cases of all malignant lesions (93.3%, 14/15). The appearance is approximately uniform signal shadow on MRI T1WI images. The lesions with different properties of the enhanced T1 images showed the imaging manifestations with their own characteristics. According to the CT and enhanced MRI images, the designed treatment plan was divided into 5 types. The coincidence rate of operation and plan was 90.5%,there were 4 cases of temporary modification in operation. Conclusion: For unilateral lesions, preoperative enhanced MRI and CT scan should be included as routine examination. CT is clear for bone observation, and can be the nature of tumor and germinal center. Enhanced MRI can provide more accurate information on the lesion scope, blood supply and the relationship between mass and surrounding tissues. Combined with the preoperative imaging data, it can provide the basis for the operation plan and treatment strategy of unilateral lesions.